Adverse events following statin-fenofibrate therapy versus statin alone: A meta-analysis of randomized controlled trials

Clinical and Experimental Pharmacology and Physiology

Volumn 40, Issue 3, 2013, Pages 219-226

  Geng, Qiang ^a   Ren, Jingyi ^a   Chen, Hong ^a   Lee, Chongyou ^a   Liang, Wenqing ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Adverse events; Fenofibrate; Meta analysis; Statin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CHOLESTEROL; CREATINE KINASE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN;

ADVERSE DRUG REACTION; ARTICLE; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; HUMAN; LIVER DYSFUNCTION; META ANALYSIS; MONOTHERAPY; MUSCLE DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SYSTEMATIC REVIEW; TOXIC HEPATITIS;

DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FENOFIBRATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; LIPIDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84874292234     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12053     Document Type: Article

References (20)

1. Cholesterol Treatment Trialists (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81.
2. Fruchart JC, Sacks FM, Hermans MP et al. The residual risk reduction initiative: A call to action to reduce residual vascular risk in dyslipidaemic patients. Diab. Vasc. Dis. Res. 2008; 5: 319-35.
3. Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG. Atorvastatin and micronized fenofibrate alone and in combination in Type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002; 25: 1198-202.
4. Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am. J. Cardiol. 2005; 5: 462-8.
5. Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). ESC/EASGuidelines for the management of dyslipidaemias. Eur. Heart J. 2011; 32: 1769-818.
6. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
7. Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. PLoS Med. 2009; 6: e1000097.
8. Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011. Available from: http://www.cochrane-handbook.org (accessed 21 March 2011).
9. Muhlestein JB, May HT, Jensen JR et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidaemia. The DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J. Am. Coll. Cardiol. 2006; 48: 396-401.
10. Krysiak R, Anna GD, Okopien B. Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in Type 2 diabetes mellitus with mixed dyslipidemia. Am. J. Cardiol. 2011; 107: 1010-18.
11. Derosa G, Maffioli P, Salvadeoa SA et al. Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in Type 2 diabetic patients. Curr. Med. Res. Opin. 2009; 25: 1973-83.
12. Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, Type 2 diabetes mellitus, and coronary heart disease: A 12-month, randomized, double-blind, controlled trial. Clin. Ther. 2004; 26: 1599-607.
13. Agouridis AP, Tsimihodimos V, Filippatos TD, Tselepis AD, Elisaf MS. High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia. Lipids 2011; 46: 521-8.
14. Shah HD, Parikh KH, Chag MC et al. Beneficial effects of the addition of fenofibrate to statin therapy in patients with acute coronary syndrome after percutaneous coronary interventions. Exp. Clin. Cardiol. 2007; 12: 91-6.
15. Davidson MH, Rooney MW, Drucker J et al. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: A 12-week, multicenter, double-blind, randomized, parallel-group study. Clin. Ther. 2009; 31: 2824-38.
16. Farnier M, Ducobu J, Bryniarski L. Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy. Am. J. Cardiol. 2010; 106: 787-92.
17. Farnier M, Steinmetz A, Retterstøl K, Császár A. Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with Type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: A double-blind, randomized comparative study. Clin. Ther. 2011; 33: 1-12.
18. ACCORD Study Group. Effects of combination lipid therapy in Type 2 diabetes mellitus. N. Engl. J. Med. 2010; 362: 1563-74.
19. Ren JY, Chen H, Luo Y. Efficacy and safety of combination therapy with simvastatin and fenofibrate for combined hyperlipidemia. Zhonghua Xin Xue Guan Bing Za Zhi. 2005; 33: 122-6.
20. Egger M. Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.